Every letter we have printed

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.

The composite test table you print as a model is unrealistic. No research supplier is going to run headspace GC and ion chromatography on every lot at these price points, and publishing an aspirational document as a benchmark just makes real certificates look worse than they are.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

Three vendors have now sent me marketing material claiming their product preserves lean mass during GLP-1 treatment, two of them citing your publication as a source for the underlying composition figures. You may want to know that.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

Your table lists orforglipron with a half-life of 29 to 49 hours. That is a wide range to report as a single figure. What accounts for it?

Your piece states that moving the injection day does not change total exposure, and I accept the arithmetic, but I want to record that it changed my experience considerably. I moved from Monday morning to Thursday evening and the two worst days now fall on a weekend. The drug is doing the same thing; my week is not.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.

You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

Thank you for saying plainly that the maximum dose is not the goal. I stopped at 10 mg fourteen months ago because it was working and I was tired of arguing about it. Every article I read before yours implied I had given up early.

I want to object to the framing of dose reduction as measurement. In practice it is experienced as failure, and telling people it is a thermostat does not change how the appointment feels. The language problem is real and you have solved it rhetorically rather than actually.

You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?

Your piece treats the four-week step as arithmetic, and I accept the arithmetic, but my prescriber moved me up every two weeks and I reached the top dose without difficulty. I do not think the schedule is as constraining as you suggest.

You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

A small technical correction. You write that trifluoroacetic acid is used at around 0.1 per cent. In peptide work concentrations of 0.05 to 0.1 per cent are both common, and some methods run higher for particularly basic sequences. The figure reads as though it were a standard rather than a range.

Acting on your section about system suitability, I asked a laboratory whether the criteria had been met on my run. They sent the suitability summary the same afternoon, unprompted and without charge, and it showed a tailing factor of 1.3 and replicate agreement well inside a per cent. Nothing was being withheld. Nobody had ever asked.

You list five things a purity figure cannot tell you and then say the list is not an indictment of the technique. It reads like one. If a measurement is silent on content, aggregation, sequence, isomers and microbiology, why is it the measurement this market uses at all?

Your table of what each method can see puts "only if resolved" against isoaspartate for RP-HPLC. That understates the difficulty. Resolving isoAsp from Asp routinely requires a method developed for the purpose, and on a generic gradient the two are frequently indistinguishable even at forty minutes.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

Your endotoxin table gives vial 12 at 112 EU per vial and then declines to say whether that is dangerous. I understand why. It is still frustrating to read a figure of that size next to the sentence "arithmetic, not a safety assessment".

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.